Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) OR HILTONOL Adjuvant Vaccine in Patients With Localized and Locally Advanced Non-Small Cell Lung Cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cancer vaccine MUC-1 (Primary) ; Poly ICLC
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 09 Jun 2021 Biomarkers information updated
- 07 Dec 2012 New trial record